C
엔케이젠바이오텍코리아
182400KOSDAQ기초 의약물질 제조업46.5 / 100
Reference Date: 2026-06-10
Financial Score14.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, Revenue is on a declining trend. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Enkmax BioTech Korea focuses on immunotherapy, immunodiagnostic kits, health supplement sales, and bio research reagents. The company utilizes its 'SuperNK' platform technology, based on NK cells, to develop immunotherapy treatments for various diseases, with global clinical trials underway. Its immunodiagnostic kits, the world's first to measure NK cell activity in whole blood, hold patents in 30 countries, and health supplements like NK365, which enhance immunity, are also a key product line.
Number of Employees
70people
Average Salary
0.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 27.714.0Point
PBR
—Industry Average 1.743.5Point
ROE
—Industry Average -6.033.5Point
Debt Ratio
57.01Industry Average 6.620.0Point
8.6x industry avg (risky)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼11.1% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲65.8% (2-year basis)
ROE Trend
0.0 / 4
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 3,670Won52-week high 3,67052-week low 3,670
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral분기보고서 (2026.03)2026-05-15